TRDA
HealthcareEntrada Therapeutics, Inc.
$10.50
+$0.45 (+4.48%)
Jan 5, 2026
Price History (1Y)
Analysis
Entrada Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $401.30M and approximately 183 employees. The company's revenue for the trailing twelve months (TTM) stands at $61.52M. The financial health of Entrada Therapeutics, Inc. reveals significant challenges. The company has reported negative profitability metrics, including a gross margin of -130.4%, operating margin of -2915.2%, and profit margin of -168.2%. Additionally, the return on equity (ROE) stands at -27.1% and return on assets (ROA) at -15.7%. The balance sheet indicates that the company has a debt-to-equity ratio of 15.38 and a current ratio of 14.08, with cash reserves totaling $326.84M and outstanding debt amounting to $52.40M. Entrada Therapeutics, Inc.'s valuation metrics are also noteworthy. The forward price-to-earnings (P/E) ratio is -2.62, indicating potential concerns about the company's profitability. The revenue growth rate over the past year has been negative at -91.8%, further contributing to these valuation concerns. Dividend information is not available, and other metrics such as earnings growth and payout ratio are also N/A or indicate no dividend payments.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $401.30M
- P/E Ratio
- N/A
- 52-Week High
- $18.42
- 52-Week Low
- $4.93
- Avg Volume
- 223.91K
- Beta
- -0.12
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 183